Precision in Motion: Decoding the Critical Operations Behind the Logistics of Next-Generation Cell and Gene Therapies
Cell and gene therapies (CGTs) are transforming personalized medicine but demand ultra‑precise logistics because they are patient‑specific, highly sensitive, and often viable for only minutes to hours. Traditional freight cannot meet the sub‑30‑minute delivery windows, cryogenic temperature requirements, and real‑time monitoring needed to preserve cell viability. Marken’s logistics platform offers an agnostic framework, 24/7 control towers, and Live‑View‑Link software that track temperature, GPS, tilt and shock in near real‑time. By leveraging dedicated UPS air‑fleet slots, chartered aircraft, and vetted local couriers, Marken ensures global, remote‑area delivery even amid geopolitical disruptions.
Viridian Data Lift Prospects for Thyroid Eye Disease Drug
Viridian Therapeutics announced that its subcutaneous drug elegrobart met primary endpoints in a Phase 3 trial for chronic thyroid eye disease, showing 50%‑54% response rates versus 15% for placebo. The once‑monthly regimen also improved double vision in 61% of patients, while...
Cytospire Hauls in $83M for a New Type of T Cell Engager
Cytospire, a London‑based biotech, closed a £61 million ($83 million) Series A round to develop a novel class of pan‑gamma‑delta T‑cell engagers. The lead candidate, CYT X300, will target EGFR‑positive solid tumours such as colorectal, head‑and‑neck, and non‑small‑cell lung cancer. By recruiting gamma‑delta T...
Celcuity Strengthens Case for ASCO-Spotlighted Breast Cancer Drug
Celcuity announced that its experimental PI3K/mTOR inhibitor gedatolisib achieved statistically significant and clinically meaningful disease‑progression delays in two‑ and three‑drug combinations for patients with PIK3CA‑mutated, hormone‑receptor‑positive, HER2‑negative breast cancer. The data will be presented at the ASCO meeting in Chicago...
What Is Your AI Drug Repurposing Strategy Missing?
The article argues that AI‑driven drug repurposing for oncology often fails because models are fed fragmented, noisy data despite abundant datasets. It stresses that more data alone won’t improve outcomes; instead, high‑quality, curated, structured data—such as knowledge graphs linking genes,...
Arvinas’ ‘Protac’ Breast Cancer Drug Cleared by FDA
The FDA approved Arvinas and Pfizer’s Veppanu, a PROTAC drug, as a second‑line therapy for metastatic ER‑positive, HER2‑negative breast cancer with ESR1 mutations. Veppanu is the first protein‑degrading medicine cleared in the U.S., targeting estrogen receptors for destruction. While the...
Merck Still Sees ‘Compelling’ Outlook for Terns Leukemia Drug
Merck agreed to acquire Terns Pharmaceuticals for $6.7 billion, paying $53 per share, after updated trial data showed its TERN‑701 leukemia drug achieving a major molecular response (MMR) rate north of 50% at 24 weeks. The data suggested TERN‑701 could outperform...
Pfizer Deals Extend Patent Life for a Top-Selling Rare Disease Drug
Pfizer announced settlements with Dexcel Pharma, Hikma Pharmaceuticals and Cipla that push the patent expiry of its rare‑disease drug Vyndamax to June 1, 2031. The deals delay generic tafamidis entry, keeping U.S. sales stable through the early 2030s after the company warned...
Veradermics Soars on Positive Data for Baldness Treatment
Veradermics announced that its experimental oral minoxidil pill, VDPHL01, achieved the primary endpoint in a Phase 3 trial, delivering a 30‑33 hair‑per‑cm² increase over six months versus placebo. The drug was well tolerated, with side‑effect rates matching placebo and no cardiac...
Lilly to Buy Startup Ajax in Bid for a Better JAK Drug
Eli Lilly announced it will acquire New York‑based biotech Ajax Therapeutics for up to $2.3 billion. The deal centers on Ajax’s experimental JAK inhibitor AJ1‑11095, which binds an inactive JAK2 conformation to overcome resistance seen with existing therapies for myelofibrosis and...
Sanofi MS Drug Rejected in US Gets an Endorsement in Europe
Sanofi’s experimental multiple‑sclerosis drug tolebrutinib, marketed as Cenrifki, received a positive recommendation from the European Medicines Agency for secondary progressive MS, after the U.S. FDA rejected it earlier this year. The EMA’s endorsement paves the way for a final approval...
Roche, Facing Biosimilar Threats, Puts Faith in New Cancer and Obesity Drugs
Roche said its emerging breast‑cancer pill giredestrant and a suite of obesity drugs could generate up to $9 billion in peak annual sales. First‑quarter sales rose 6% to 14.7 billion Swiss francs (≈$18.8 billion) but fell 5% on currency effects, and the company...
Sanofi Posts Upbeat Sales as R&D Pressure Builds
Sanofi reported first‑quarter net sales of €10.5 billion (about $12.3 billion), a 6.2% rise that beat Wall Street forecasts, driven largely by a 31% jump in Dupixent revenue. The French group reaffirmed its 2026 outlook, expecting high‑single‑digit sales growth and earnings that...
Merck’s Fast-Ascending Kidney Cancer Drug Hits a Setback
Merck announced that Welireg, combined with Keytruda and Lenvima, failed to meet primary endpoints in a Phase 3 first‑line clear‑cell renal cell carcinoma trial, missing both progression‑free and overall survival benefits. The setback curtails Merck’s plan to use Welireg to offset...
BioAge Says Early Data Suggest ‘Best-in-Class’ Potential for Inflammation Drug
BioAge Labs released Phase 1 data for the 60‑mg dose of its NLRP3 inhibitor BGE‑102, confirming tolerability and inflammation‑lowering activity similar to the earlier 120‑mg readout. The oral pill crosses the blood‑brain barrier, opening possibilities for cardiovascular, obesity, eye and central‑nervous‑system...
AACR 2026: Revolution’s Next Prospect, Merck’s Reveal and a Lung Cancer Battle
At AACR 2026, Revolution Medicines reported that its RAS‑G12D inhibitor zoldonrasib produced a 52% response rate and a median 11.1‑month progression‑free survival in heavily pre‑treated non‑small cell lung cancer (NSCLC) patients, hinting at accelerated‑approval potential. Merck presented early data on...
![[Podcast] From Protocol to Patient: Inside Clinical Supply with Almac Clinical Services](https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/e66ba866d739cb77f8cd3922f2eb37b8.webp)
[Podcast] From Protocol to Patient: Inside Clinical Supply with Almac Clinical Services
Almac Clinical Services has launched a six‑part podcast series that walks listeners through the end‑to‑end clinical supply chain, from protocol translation to global regulatory release. The series targets biopharma sponsors, highlighting how early collaboration with supply partners can streamline planning,...
What Actually Drives Speed in Complex Drug Development Programs
Speed in complex drug development is less about pushing harder and more about early, cross‑functional coordination. Traditional sequential handoffs often create hidden delays, forcing teams to revisit decisions under pressure. Thermo Fisher Scientific’s Accelerator™ Drug Development model integrates CDMO and...
Terremoto Raises $108M to Pursue Development of Drugs Targeting AKT
Terremoto Biosciences announced a $108 million Series C round to accelerate its oral AKT‑targeting drug platform. The biotech currently has its lead candidate, TER‑2013, in a Phase 1 trial for solid tumors with specific genetic alterations, and plans to start clinical testing of...
Obsidian, Galera to Advance Cell Therapy Following Reverse Merger
Obsidian Therapeutics will go public on Nasdaq via a reverse merger with Galera Therapeutics, creating a combined entity focused on OBX-115, a tumor‑infiltrating lymphocyte (TIL) cell therapy. OBX-115 is in mid‑stage melanoma and early‑stage lung‑cancer trials and is designed to...
Connected Medical Devices: Smarter Care Starts Here
Connected medical devices (CMD) are becoming essential for gathering real‑world patient data and supporting decentralized clinical trials. Their integration—from wearable biosensors to continuous glucose monitors—requires dedicated service lines that manage calibration, storage, and data flow. Companies such as Marken are...
Rethinking Dermatology Trial Design for Late-Stage Success
Advances in immunology have spurred many new dermatology therapies, but late‑stage trial failures often stem from outdated trial designs. Traditional short‑term efficacy endpoints like PASI or EASI miss critical data on durability, patient‑reported outcomes, and long‑term safety. Experts advocate incorporating...
Oricell Closes a ‘Pre-IPO’ Megaround to Aim CAR-T at Solid Tumors
Oricell Therapeutics, a Shanghai‑based biotech, closed a pre‑IPO financing round of more than $110 million to accelerate its CAR‑T programs targeting solid tumors, starting with liver cancer. Its lead candidate, Ori‑C101, targets the GPC3 protein and has shown a 60% response...
Jeito Capital, Prominent Biotech Investor, Raises $1.2B for Next Fund
Jeito Capital announced the close of its Jeito II fund, raising €1 billion (about $1.2 billion) – the largest capital raise ever for an independent European biopharma fund. The fund will back 15‑20 clinical‑stage drugmakers, allocating up to €150 million ($162 million) per company across...
Terns Rebuffed a Higher Bid Before Selling to Merck
Terns Pharmaceuticals accepted Merck & Co.'s $53‑per‑share, $6.7 billion buyout, a price roughly 15% below an earlier $61 offer from an unnamed Party C. Party C’s proposal included a contingent $9‑per‑share payout tied to FDA approval of TERN‑701, but it withdrew after updated...
Gilead Continues M&A Surge with $3.1B Deal for ADC Specialist Tubulis
Gilead Sciences announced a deal to acquire German biotech Tubulis for $3.15 billion upfront, potentially rising to $5 billion with milestones. The purchase adds a next‑generation antibody‑drug conjugate (ADC) platform and two clinical candidates, TUB‑040 and TUB‑030, to Gilead’s oncology pipeline. This...
Sanofi Immune Drug Hopeful Posts Mixed Results in Mid-Stage Tests
Sanofi reported mixed Phase 2 results for its bispecific antibody lunsekig. The drug achieved its primary and key secondary endpoints in moderate‑to‑severe asthma and chronic rhinitis with nasal polyps, showing reduced exacerbations, improved lung function and smaller polyps. Conversely, lunsekig failed...
Hims & Hers Says Limited Data Stolen in Social Engineering Attack
Hims & Hers disclosed a sophisticated social‑engineering breach that compromised its third‑party customer‑service platform from February 4‑7, 2026. Hackers accessed service tickets, exposing customer names and email addresses, but the firm confirmed that electronic medical records and provider communications were untouched....
Under-the-Skin Tepezza Comparable to Infused Version in Key Study, Amgen Says
Amgen announced that its subcutaneous on‑body injector version of Tepezza, called Tepezza OBI, met both primary and key secondary endpoints in a late‑stage trial, showing 77% of patients achieved a meaningful reduction in eye bulging. The efficacy was comparable to...
Neurocrine to Acquire Prader-Will Drug in $2.9B Soleno Buyout
Neurocrine Biosciences agreed to acquire Soleno Therapeutics for $2.9 billion, securing the rare‑disease drug Vykat XR. Vykat generated $190 million in 2025 sales, including $92 million in the fourth quarter, but recent safety concerns and a slowdown in new patient starts have clouded its...
Perks Persuade Participants
Clinical trial sponsors are shifting from cash and checks to reloadable incentive cards to streamline participant compensation. Reloadable cards function like debit cards, allowing multiple reloads, real‑time tracking, and universal acceptance. InComm InCentives' Participant Perks Card offers a Visa‑branded, white‑label...
White House Seeks 12% Cut to HHS in 2027
The White House’s FY 2027 budget request calls for a 12.5% cut to the Department of Health and Human Services, slashing $15.8 billion from the agency’s discretionary budget. The proposal trims NIH funding by $5 billion, eliminates the National Institute on Minority Health...
Pfizer, BioNTech to Pause COVID Vaccine Study Due to Low Enrollment
Pfizer and BioNTech announced the suspension of a FDA‑mandated post‑marketing study of their COVID‑19 vaccine due to insufficient participant enrollment. The trial, aimed at 25,500 adults aged 50‑64, was designed to assess safety, immune response, and efficacy against infection. Companies...
FDA, After Turbulent Year, Leaves Drugmakers Guessing on Its Direction
The FDA’s leadership turmoil has intensified under Commissioner Marty Makary, with the agency cycling through multiple heads of its CDER and CBER centers in just over a year. Public‑facing comments from senior officials have sparked sharp stock moves, most notably...
Biogen, with $5.6B Apellis Buy, Builds Out Immunology Offerings
Biogen announced a $5.6 billion cash acquisition of Apellis Pharmaceuticals, paying $41 per share—a 140% premium—and issuing contingent value rights worth up to $4 per share. The deal brings two recently launched products, the eye‑disease therapy Syfovre and the rare‑kidney drug...
Merck Strikes Deal with Antibody Discovery Startup
Merck has signed a research collaboration with AI‑driven antibody startup Infinimmune, potentially providing up to $838 million in payments tied to clinical milestones. Infinimmune’s platform scans human immune cells to uncover novel targets such as IL‑22 and IL‑13 for autoimmune indications....
Blackstone Closes $6.3B Fund for Life Sciences Investing
Blackstone announced the closing of a $6.3 billion life‑sciences private fund, the largest ever raised in the sector and roughly 40% bigger than its 2020 predecessor. The new vehicle expands the Blackstone Life Sciences (BXLS) platform, which now manages about $15 billion...
Risk, Readiness and Resilience
Life‑sciences firms are confronting compressed validation timelines, tighter regulatory oversight and fragile supply chains, prompting a shift from cost‑driven to confidence‑driven site selection. Middlesex County, New Jersey, offers that confidence through a highly educated talent pool, continuous university‑backed research, and deep...
Rhythm Obesity Drug Wins Broader Use From FDA
The FDA approved Rhythm Pharmaceuticals' once‑daily injection Imcivree for acquired hypothalamic obesity in adults and children aged four and up. Clinical trials showed an 18‑percentage‑point weight‑loss advantage over placebo, making it the first therapy for this rare, brain‑injury‑driven condition. Rhythm...
Crossbow Raises $77M for New Cancer Immunotherapies
Crossbow Therapeutics announced a $77 million Series B round to push its TCR‑mimetic antibody platform toward clinical reality. The company’s lead candidate, CBX‑250, demonstrated robust tumor‑cell killing with limited healthy‑cell damage in preclinical models and is now enrolling a Phase 1 trial for...
Bicycle to Lay Off 30% of Staff, Pivot Away From Padcev Challenger
Biotech firm Bicycle Therapeutics announced it will lay off roughly 30% of its workforce, about 86 employees, as it deprioritizes its experimental ADC zelenectide‑pevedotin. Regulators expressed doubts that the Phase 2 Duravelo‑2 trial data will support accelerated approval for metastatic bladder...
CytomX Surges on Positive Data for ‘Masked’ ADC in Colorectal Cancer
CytomX Therapeutics’ shares surged 66% after the company released expansion data from its Phase 1 study of Varseta‑M, a masked antibody‑drug conjugate targeting EpCAM in late‑stage colorectal cancer. The trial evaluated three dose levels, with the two highest doses achieving response...
Vertex Kidney Disease Drug Hits Mark in Late-Stage Study
Vertex Pharmaceuticals announced that its experimental IgA nephropathy drug povetacicept met primary and key secondary endpoints in a Phase 3 trial, cutting urine protein by roughly 50% versus placebo after 36 weeks. The interim results also showed reductions in abnormal antibodies...
Rethinking the Box: Why Circular Cold Chain Packaging Is Becoming a Cost Strategy in Healthcare
Healthcare logistics is moving from disposable to circular cold chain packaging, turning boxes into reusable infrastructure. Studies show reusable containers can lower per‑shipment costs by 30‑50% and cut global warming potential by 75%. By engineering packs to reduce dimensional weight,...
Navigating the PPQ Process: Proven Strategies to Safeguard Quality for Cell and Gene Therapies
Process Performance Qualification (PPQ) is the final validation step before commercial manufacturing of cell and gene therapies, but its complexity often triggers delays and compliance risks. The article highlights three proven strategies—early master‑plan development, continuous quality improvement, and data‑driven analytics—to...
Kyowa Kirin Abandons Touted Eczema Drug Following Safety Review
Kyowa Kirin announced it will cease all clinical trials of rocatinlimab, an anti‑OX40 antibody once touted as a potential eczema blockbuster, after a safety review identified emerging malignancy signals. The review, conducted with former partner Amgen, uncovered a confirmed and...
Candid, in a Reverse Merger with RallyBio, to Go Public
Candid Therapeutics is merging with Rallybio in a reverse merger, creating a publicly traded company under the CDRX ticker. The deal is backed by a $505 million private financing round that attracted over a dozen venture and institutional investors. Candid’s pipeline...
Safety Concerns Spur Aardvark to Halt Key Prader-Willi Drug Trial
Biotech Aardvark Therapeutics announced a voluntary pause of the Phase 3 HERO trial for its Prader‑Willi drug ARD‑101 after routine safety monitoring identified reversible cardiac observations in healthy volunteers receiving supratherapeutic doses. The pause affects both the main trial and an...
Why It’s Critical to Close Open Steps in Cell Therapy Manufacturing
Cell therapy manufacturing is vulnerable to contamination because living cells cannot be terminally sterilized. Regulatory bodies such as EU GMP Annex 1 and the FDA now require risk‑based contamination control strategies that prioritize closed, sterile, and automated processes. Closing open steps...
Bristol Myers Says ADC Licensed From China Hits Mark in Aggressive Breast Cancer
Bristol Myers Squibb reported that its antibody‑drug conjugate iza‑bren, licensed from Chinese partner SystImmune, achieved statistically significant improvements in progression‑free and overall survival versus chemotherapy in a Phase III trial for advanced triple‑negative breast cancer. The study, conducted in mainland China...